NasdaqGS - Nasdaq Real Time Price USD

ImmunityBio, Inc. (IBRX)

Compare
4.2100 -0.0400 (-0.94%)
At close: August 26 at 4:00 PM EDT
4.2900 +0.08 (+1.90%)
After hours: August 26 at 5:54 PM EDT
Loading Chart for IBRX
DELL
  • Previous Close 4.2500
  • Open 4.2700
  • Bid 4.1700 x 300
  • Ask 4.2600 x 300
  • Day's Range 4.1800 - 4.4300
  • 52 Week Range 1.2500 - 10.5300
  • Volume 2,198,533
  • Avg. Volume 3,228,230
  • Market Cap (intraday) 2.932B
  • Beta (5Y Monthly) -0.31
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9600
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.38

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

immunitybio.com

622

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IBRX

View More

Performance Overview: IBRX

Trailing total returns as of 8/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

IBRX
16.14%
S&P 500
17.76%

1-Year Return

IBRX
155.15%
S&P 500
27.49%

3-Year Return

IBRX
62.78%
S&P 500
24.92%

5-Year Return

IBRX
231.50%
S&P 500
97.28%

Compare To: IBRX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IBRX

View More

Valuation Measures

Annual
As of 8/26/2024
  • Market Cap

    2.93B

  • Enterprise Value

    3.45B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.03k

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.64k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -61.04%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.31M

  • Net Income Avi to Common (ttm)

    -597.65M

  • Diluted EPS (ttm)

    -0.9600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    217.98M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -273.73M

Research Analysis: IBRX

View More

Company Insights: IBRX

Research Reports: IBRX

View More

People Also Watch